Dendritic cell–based immunotherapy: state of the art and beyond KF Bol, G Schreibelt, WR Gerritsen, IJM De Vries, CG Figdor Clinical cancer research 22 (8), 1897-1906, 2016 | 364 | 2016 |
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors JFM Jacobs, AJ Idema, KF Bol, S Nierkens, OM Grauer, P Wesseling, ... Neuro-oncology 11 (4), 394-402, 2009 | 283 | 2009 |
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic CellsMyeloid DCs Induce Effective Responses in Melanoma Patients G Schreibelt, KF Bol, H Westdorp, F Wimmers, EHJG Aarntzen, ... Clinical cancer research 22 (9), 2155-2166, 2016 | 240 | 2016 |
Prognostic significance and mechanism of Treg infiltration in human brain tumors JFM Jacobs, AJ Idema, KF Bol, JA Grotenhuis, IJM de Vries, P Wesseling, ... Journal of neuroimmunology 225 (1-2), 195-199, 2010 | 232 | 2010 |
Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination EHJG Aarntzen, IJM De Vries, WJ Lesterhuis, D Schuurhuis, JFM Jacobs, ... Cancer research 73 (1), 19-29, 2013 | 176 | 2013 |
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells KF Bol, G Schreibelt, K Rabold, SK Wculek, JK Schwarze, A Dzionek, ... Journal for immunotherapy of cancer 7 (1), 1-13, 2019 | 158 | 2019 |
Dendritic cell cancer therapy: vaccinating the right patient at the right time WW Van Willigen, M Bloemendal, WR Gerritsen, G Schreibelt, ... Frontiers in Immunology 9, 2265, 2018 | 133 | 2018 |
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma … EHJG Aarntzen, G Schreibelt, K Bol, WJ Lesterhuis, AJ Croockewit, ... Clinical Cancer Research 18 (19), 5460-5470, 2012 | 125 | 2012 |
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity KF Bol, EHJG Aarntzen, JM Pots, MAM Olde Nordkamp, ... Cancer Immunology, Immunotherapy 65 (3), 327-339, 2016 | 78 | 2016 |
Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients KF Bol, HW Mensink, EHJG Aarntzen, G Schreibelt, JEE Keunen, ... American journal of ophthalmology 158 (5), 939-947. e5, 2014 | 77 | 2014 |
Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma EHJG Aarntzen, K Bol, G Schreibelt, JFM Jacobs, WJ Lesterhuis, ... Cancer research 72 (23), 6102-6110, 2012 | 72 | 2012 |
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination KF Bol, EHJG Aarntzen, FEM Hout, G Schreibelt, JHA Creemers, ... Oncoimmunology 5 (1), e1057673, 2016 | 71 | 2016 |
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients KF Bol, CG Figdor, EHJG Aarntzen, MEB Welzen, MM van Rossum, ... Oncoimmunology 4 (8), e1019197, 2015 | 67 | 2015 |
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer RS Laureano, J Sprooten, I Vanmeerbeerk, DM Borras, J Govaerts, ... Oncoimmunology 11 (1), 2096363, 2022 | 66 | 2022 |
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial S Boudewijns, M Bloemendal, N de Haas, H Westdorp, KF Bol, ... Cancer Immunology, Immunotherapy 69, 477-488, 2020 | 56 | 2020 |
Adjuvant dendritic cell vaccination in high-risk uveal melanoma KF Bol, T Van den Bosch, G Schreibelt, HW Mensink, JEE Keunen, E Kiliç, ... Ophthalmology 123 (10), 2265-2267, 2016 | 50 | 2016 |
Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma KF Bol, E Ellebaek, L Hoejberg, MM Bagger, MS Larsen, TW Klausen, ... Cancers 11 (10), 1489, 2019 | 47 | 2019 |
Naturally circulating dendritic cells to vaccinate cancer patients KF Bol, J Tel, IJM De Vries, CG Figdor Oncoimmunology 2 (3), e23431, 2013 | 42 | 2013 |
T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell VaccinesT-cell Ratio Predicts … A Vasaturo, A Halilovic, KF Bol, DI Verweij, WAM Blokx, CJA Punt, ... Cancer research 76 (12), 3496-3506, 2016 | 41 | 2016 |
Human pDCs are superior to cDC2s in attracting cytolytic lymphocytes in melanoma patients receiving DC vaccination JJP van Beek, G Flórez-Grau, MAJ Gorris, TSM Mathan, G Schreibelt, ... Cell reports 30 (4), 1027-1038. e4, 2020 | 36 | 2020 |